Cargando…
Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393490/ https://www.ncbi.nlm.nih.gov/pubmed/34440345 http://dx.doi.org/10.3390/genes12081171 |
_version_ | 1783743738268352512 |
---|---|
author | Thakur, Kavita Singh, Manu Smriti Feldstein-Davydova, Sara Hannes, Victoria Hershkovitz, Dov Tsuriel, Shlomo |
author_facet | Thakur, Kavita Singh, Manu Smriti Feldstein-Davydova, Sara Hannes, Victoria Hershkovitz, Dov Tsuriel, Shlomo |
author_sort | Thakur, Kavita |
collection | PubMed |
description | Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA) and cell-free DNA (cfDNA) for identifying tumor mutations in patients with colon carcinoma. Method: DNA was extracted from the tumor tissue of 33 patients diagnosed with colon carcinoma. Targeted NGS panel, based on the hotspots panel, was used to identify tumor mutations. Pre-surgery serum and plasma were taken from the patients in which mutation was found in the tumor tissue. Extracellular vesicles were isolated from the serum followed by the extraction of EV-DNA. CfDNA was extracted from the plasma. The mutations found in the tumor were used to detect the circulating tumor DNA using ultra-deep sequencing. We compared the sensitivity of mutation detection and allele frequency obtained in EV-DNA and cfDNA. Results: The sensitivity of mutation detection in EV-DNA and cfDNA was 61.90% and 66.67%, respectively. We obtained almost identical sensitivity of mutation detection in EV-DNA and cfDNA in each of the four stages of colon carcinoma. The total DNA concentration and number mutant copies were higher in cfDNA vs. EV-DNA (p value = 0.002 and 0.003, respectively). Conclusion: Both cfDNA and EV-DNA can serve as tumor biomarkers. The use of EV-DNA did not lead to improved sensitivity or better detection of tumor DNA in the circulation. |
format | Online Article Text |
id | pubmed-8393490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83934902021-08-28 Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer Thakur, Kavita Singh, Manu Smriti Feldstein-Davydova, Sara Hannes, Victoria Hershkovitz, Dov Tsuriel, Shlomo Genes (Basel) Article Liquid biopsy has emerged as a promising non-invasive way to diagnose tumor and monitor its progression. Different types of liquid biopsies have different advantages and limitations. In the present research, we compared the use of two types of liquid biopsy, extracellular vesicle-derived DNA (EV-DNA) and cell-free DNA (cfDNA) for identifying tumor mutations in patients with colon carcinoma. Method: DNA was extracted from the tumor tissue of 33 patients diagnosed with colon carcinoma. Targeted NGS panel, based on the hotspots panel, was used to identify tumor mutations. Pre-surgery serum and plasma were taken from the patients in which mutation was found in the tumor tissue. Extracellular vesicles were isolated from the serum followed by the extraction of EV-DNA. CfDNA was extracted from the plasma. The mutations found in the tumor were used to detect the circulating tumor DNA using ultra-deep sequencing. We compared the sensitivity of mutation detection and allele frequency obtained in EV-DNA and cfDNA. Results: The sensitivity of mutation detection in EV-DNA and cfDNA was 61.90% and 66.67%, respectively. We obtained almost identical sensitivity of mutation detection in EV-DNA and cfDNA in each of the four stages of colon carcinoma. The total DNA concentration and number mutant copies were higher in cfDNA vs. EV-DNA (p value = 0.002 and 0.003, respectively). Conclusion: Both cfDNA and EV-DNA can serve as tumor biomarkers. The use of EV-DNA did not lead to improved sensitivity or better detection of tumor DNA in the circulation. MDPI 2021-07-29 /pmc/articles/PMC8393490/ /pubmed/34440345 http://dx.doi.org/10.3390/genes12081171 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Thakur, Kavita Singh, Manu Smriti Feldstein-Davydova, Sara Hannes, Victoria Hershkovitz, Dov Tsuriel, Shlomo Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer |
title | Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer |
title_full | Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer |
title_fullStr | Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer |
title_full_unstemmed | Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer |
title_short | Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer |
title_sort | extracellular vesicle-derived dna vs. cfdna as a biomarker for the detection of colon cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393490/ https://www.ncbi.nlm.nih.gov/pubmed/34440345 http://dx.doi.org/10.3390/genes12081171 |
work_keys_str_mv | AT thakurkavita extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer AT singhmanusmriti extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer AT feldsteindavydovasara extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer AT hannesvictoria extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer AT hershkovitzdov extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer AT tsurielshlomo extracellularvesiclederiveddnavscfdnaasabiomarkerforthedetectionofcoloncancer |